Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

EGFR-TKI inhibitor based on investigator's choice

Small molecule · Inhibitor of epidermal growth factor receptor (EGFR) · developed by ArriVent BioPharma

Phase 3 Most advanced trial

AVBP Developer

1 Registered trials

What is EGFR-TKI inhibitor based on investigator's choice?

EGFR-TKI inhibitor based on investigator's choice is a placeholder for an epidermal growth factor receptor tyrosine kinase inhibitor selected by the investigator, with osimertinib or afatinib named as the options. It is studied in non-small-cell lung cancer, including metastatic and advanced disease with uncommon EGFR mutations.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Targets: epidermal growth factor receptor (EGFR)
Mechanism: Inhibitor of epidermal growth factor receptor (EGFR)
Therapy area: Oncology
Developer: ArriVent BioPharma, Inc. (AVBP)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07185997	Phase 3	Non-Small-Cell Lung Cancer	Recruiting	AVBP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Non-Small-Cell Lung CancerEGFR P-Loop and Alpha C-Helix CompressingEGFR PACCEGFR Uncommon MutationsMetastatic Non-Small-Cell Lung CancerNon-Small-Cell Lung Cancer

Other drugs acting on EGFR

Neratinib FDA approved Osimertinib FDA approved Actinium Ac 225 FPI-2068 Phase 1 ALX2004 Phase 1 BH-30643 Phase 1/2 CUDC-101 Phase 1 Enozertinib Phase 1/2 Ficerafusp Alfa Phase 2/3 Firmonertinib Phase 3 FPI-2053 Phase 1 Izalontamab Brengitecan Phase 2/3 Silevertinib Phase 1/2

More from ArriVent BioPharma

ARR-002 Phase 1 ARR-217 Phase 1 Firmonertinib Phase 3

Sources

ClinicalTrials.gov NCT07185997

Updated Oct 11, 2026. Something wrong or missing? Report it on the AVBP page.

Follow AVBP, the company behind EGFR-TKI inhibitor based on investigator's choice

See AVBP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AVBP catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z